{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.43","paramType":"Hazard Ratio (HR)","paramValue":"1.29","statisticalMethod":"Regression, Cox"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.80","paramType":"C-statistic","paramValue":"0.47","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.02","value":"0.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Prediction efficacy is estimated using a hazard ratio (HR) and C-statistic (C-stat). Progression free survival is defined as the span of time from day 1 of therapy to date of disease recurrence (measured in months). Results are pooled with subjects from a pilot RDRC study for a total of 25 subjects analyzed. The Patlak influx rate, measured in l /min, is the rate of transport of FLT from blood into the tissue as well as the rate of molecular change of FLT, using a Patlak analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Subjects receive 2 18F-Fluorothymidine PET scans\n\n* Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)\n* Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)\n\nF-18 Fluorothymidine dose = 0.04 to 0.08 mCi/kg (maximum of 5 mCi +/- 10%).\n\nImaging technology: PET scan","id":"OG000","title":"FLT PET Scan"}],"paramType":"MEAN","populationDescription":"Participants who underwent the mid-therapy FLT PET scan","reportingStatus":"POSTED","timeFrame":"36 months","title":"Efficacy of the Patlak Influx Rate Constant for FLT (K-Patlak) Mid-therapy in Predicting Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"l/min"}